Demographics and clinical characteristics of the 216 individuals admitted with gout. Values are n (%) unless otherwise specified.
| Characteristics | Total |
|---|---|
| Male | 169 (78.2) |
| Age, yrs, mean (range) | 71.2 (27–99) |
| Ethnicity | |
| NZ European/European | 172 (79.6) |
| Maori/Pacific Island | 32 (14.8) |
| Comorbidities | |
| Type 2 diabetes mellitus | 61 (28.2) |
| Cardiovascular disease | 141 (65.3) |
| Cerebrovascular disease | 46 (21.3) |
| CKD, eGFR < 60 ml/min/1.73 m2, n = 205 | 128 (59.3) |
| ≥ 2/4 comorbidities | 96 (44.4) |
| Medications | |
| ACE inhibitor | 72 (33.3) |
| Diuretic | 86 (39.8) |
| α blocker | 27 (12.5) |
| β blocker | 112 (51.9) |
| Calcium channel blocker | 36 (16.7) |
| Aspirin | 97 (44.9) |
| Lipid-lowering agent | 77 (35.6) |
| ≥ 3 other medications | 110 (50.9) |
NZ: New Zealand; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ACE: angiotensin-converting enzyme.